Primary Investors


Over $800 Billion

Assets Under Management


We partner with pharmaceutical, biotech and medical technology companies to address unmet medical needs and improve the quality of life of patients around the world.


Filling a Void

Blackstone Life Sciences (BXLS) fills a critical void in the industry. While life sciences is seeing unprecedented innovation driven by rapid advancements in science and technology, it often lacks the necessary funding to bring medicines and healthcare technologies to market. We work in partnership with the pharmaceutical, biotechnology and medical technology industries to help meet this need.


$2.5 Billion

Raised in Life Science Funds


We are Abingworth, a transatlantic bioscience investment firm with a deep understanding of both the science and markets we invest in.

For over 30 years, Abingworth has been working alongside entrepreneurs to develop their ideas into products that have a dramatic impact on health. With a broad transatlantic approach to backing innovation, we invest in drugs, devices and diagnostics from seed-stage start-ups to publicly traded companies.